Applied Genetic Technologies (AGTC) Misses Q4 EPS by 20c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Chardan Capital Markets Downgrades Applied Genetic Technologies Corp. (AGTC) to Neutral
September 11, 2018 6:23 AM EDTChardan Capital Markets analyst Gbola Amusa downgraded Applied Genetic Technologies Corp. (NASDAQ: AGTC) from Buy to Neutral with a price target of $5.00 (from $10.00) on competitor progress, amid AGTC delays.
Amusa commented, "We downgrade AGTC to Neutral (+ bias), and reduce our PT to $5, after consolidating disease models from our recent work on high-conviction picks, Nightstar Therapeutics (Buy) and MeiraGTx (Buy).... More
